AstraZeneca wins patent infringement case over Farxiga generic

AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga (dapagliflozin).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AbbVie and AstraZeneca settle cancer drug patent suits

25 October 2019 AbbVie and AstraZeneca reached a settlement over patent suits involving their rival cancer drugs earlier this week, after nearly two years of litigation.

Americas

Acorda and AstraZeneca claim victory over Mylan

21 March 2016 The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.

Biotechnology

AstraZeneca inks $730m licensing deal for rare heart disease treatment

11 January 2022 Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy.

More on this story

Americas

AbbVie and AstraZeneca settle cancer drug patent suits

25 October 2019 AbbVie and AstraZeneca reached a settlement over patent suits involving their rival cancer drugs earlier this week, after nearly two years of litigation.

Americas

Acorda and AstraZeneca claim victory over Mylan

21 March 2016 The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.

Biotechnology

AstraZeneca inks $730m licensing deal for rare heart disease treatment

More on this story

Americas

AbbVie and AstraZeneca settle cancer drug patent suits

25 October 2019 AbbVie and AstraZeneca reached a settlement over patent suits involving their rival cancer drugs earlier this week, after nearly two years of litigation.

Americas

Acorda and AstraZeneca claim victory over Mylan

21 March 2016 The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.

Biotechnology

AstraZeneca inks $730m licensing deal for rare heart disease treatment